ChabioTech Obtains Japanese Patent for 'Enhanced Umbilical Cord-Derived Adhesive Stem Cells'
[Asia Economy Reporter Kum Boryeong] Cha Biotech announced on the 15th that it has acquired a Japanese patent related to 'Improved Umbilical Cord-Derived Adherent Stem Cells, Their Manufacturing Method, and Their Use.'
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Over 7,000 Residents Evacuate Urgently" Magnitude 5.2 Earthquake Leaves 2 Dead, 6 Injured... What Happened in China?
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Cha Biotech stated, "The improved umbilical cord-derived adherent stem cells have anti-inflammatory effects, vascular regeneration effects, or nerve regeneration effects, and are usefully applied in pharmaceutical compositions or cell therapies for the treatment or prevention of various diseases." They added, "In the future, when conducting regenerative medicine business including clinical trials of cell therapies in Japan, we plan to utilize this to establish a technical foundation for new drug substances and manufacturing methods, and to secure a preemptive position through patent rights protection."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
